TL;DR
The intervention with the largest, most consistent live-birth effect is freeze-all → FET in a natural cycle: the same embryo transferred to a better-lined cycle has materially higher LBR. Intrauterine PRP is the best-supported adjuvant (LBR RR 2.46 in 8-RCT meta-analysis). Hysteroscopy before cycle 2 is reasonable given my tubal occlusion history (raises pre-test probability of cavity pathology). G-CSF improves thickness but doesn't reliably translate to pregnancy. L-arginine and vitamin E: weak / negative evidence.
Papers
BMC Pregnancy Childbirth · 2024
Liu X et al. Efficacy of platelet-rich plasma in the treatment of thin endometrium: a meta-analysis of randomized controlled trials
PMC
Finding: 8 RCTs, n=678. Intrauterine PRP improved thickness (+1.23 mm), clinical pregnancy (RR 2.04), live birth (RR 2.46, 95% CI 1.57–3.85), and implantation (RR 2.71). Miscarriage unchanged.
Front Endocrinol · 2025
Keng F et al. Network meta-analysis on the efficacy of different interventions for treating thin endometrium
DOI
Finding: 18 RCTs, n=2,152. For thickness: G-CSF ranks #1 (SUCRA 78%) > aspirin > PRP. For clinical pregnancy: PRP ranks #1 (SUCRA 80%) > aspirin > G-CSF. G-CSF wins on the surrogate, PRP wins on the outcome that matters.
Hum Reprod · 2025
Genovese H et al. Does endometrial thickness impact live birth rate following a frozen embryo transfer: outcomes of 30,676 euploid single embryo transfers
PubMed
Finding: Largest dataset of its kind (25 centers, 3 countries). Thin endometrium in FET depressed LBR by 22% in programmed cycles and 41% in modified-natural cycles, but the effect was not significant in fully natural cycles. Thin lining is most forgiving in a true natural-cycle FET.
Summary — evidence-based algorithm for cycle 2
- Hysteroscopy before cycle 2. Rules out Asherman / occult cavity pathology. The tubal occlusion history raises pre-test probability that the cavity needs evaluation. Strong, expected-value-positive even if it finds nothing.
- Default to freeze-all + FET if endometrium tracks <7 mm again at trigger. Same embryo, better lining.
- For the FET, prefer a true natural cycle (not programmed) per Genovese 2025. Confirm ovulation by LH surge / progesterone.
- Adjuvants on the next stim, in order of evidence:
- Intrauterine PRP — best LBR evidence (Liu 2024, Keng 2025). Usually 0.5–1 mL, 1–2 infusions in proliferative phase. Confirm availability at each CZ clinic.
- Vaginal sildenafil 25 mg QID from CD2 → trigger. Improves thickness and clinical pregnancy; LBR data thin but it's low cost, low risk.
- Low-dose aspirin 75–100 mg/day — second in network meta-analysis, cheap.
- Estrogen route swaps (vaginal / transdermal) — small effect.
- G-CSF — keep as a rescue at trigger if lining still <6 mm. Thickness effect but not pregnancy in pooled data.
- Skip: vitamin E + pentoxifylline, growth hormone (immature evidence), stem cell therapy.
Relation to my history
My March 2026 endometrium tracked: 3.5 → 3.9 → 2.8 → 4.4 → 4.9 → 6.1 mm across the stim cycle, with Clomid in the mix (Clomid is antiestrogenic on the endometrium, which letrozole specifically avoids). The trial cohort in the Zhao 2026 letrozole paper specifically called out the 6–7 mm subgroup: zero live births in either arm (small subgroup, n=13). So my Grace transfer was attempted at a lining where success is rare regardless of protocol.
Confidence: how well each finding applies to me
| Finding | Confidence | Note |
|---|
| Freeze-all → natural-cycle FET protects against thin-lining LBR drop | High | Genovese 2025 is the largest dataset. I'm ovulatory; natural cycle is feasible. |
| Intrauterine PRP improves LBR in thin lining | Medium | RR 2.46 is unusually large — expect regression as bigger RCTs publish. Real but probably smaller in real-world use. |
| Hysteroscopy is worth doing before cycle 2 | High | Asherman / chronic endometritis is the kind of finding that explains a thin lining + failed transfer. |
| G-CSF improves thickness but not pregnancy | Medium | Cochrane rates evidence as low; useful when thickness is the bottleneck but not as an LBR booster. |
| Clomid contributed to my thin lining | Medium | Plausible mechanism (antiestrogenic on endometrium) but not directly tested in my cycle. |
| Vitamin E / pentoxifylline / L-arginine | Low | Pilots / case series only. Skip or de-prioritize. |
Questions to raise with each CZ clinic
- Do you offer hysteroscopy before cycle 2 to evaluate the cavity, given my prior failed transfer + tubal occlusion history?
- Do you offer intrauterine PRP? At what timing and what's your protocol?
- If my endometrium tracks <7 mm again at trigger, what's the default — proceed fresh, or freeze-all and FET in a later natural cycle?
- Will you avoid Clomid co-administration during stim given its known antiestrogenic effect on the endometrium?
Caveats
- The PRP literature is enthusiastic but young — the LBR effect size will likely shrink in larger RCTs.
- Endometrial thickness is a flawed surrogate. Pattern (trilaminar vs homogeneous), sub-endometrial flow, and receptivity also matter. The 7 mm cutoff is a soft threshold; the LBR curve drops continuously, not sharply.